Turn Therapeutics to present at Jefferies conference

Turn Therapeutics Inc. filed a current report to share that its CEO, Bradley Burnam, will present at the Jefferies Global Healthcare Conference in New York City on June 4, 2026, from 9:55 AM to 10:25 AM EDT.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Turn Therapeutics Inc. filed a current report to share that its CEO, Bradley Burnam, will present at the Jefferies Global Healthcare Conference in New York City on June 4, 2026, from 9:55 AM to 10:25 AM EDT. A live webcast and a replay for about six months will be available on the company’s investor relations website. The company highlights its lead investigational therapy GX-03, a topical inhibitor for moderate-to-severe atopic dermatitis targeting IL-36 and IL-31, which is in a Phase 2 randomized controlled trial with topline results expected in mid-2026.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Conference presentation date: June 4, 2026 Presentation time window: 9:55 AM–10:25 AM EDT Webcast replay duration: Approximately six months +2 more

5 metrics

Conference presentation date June 4, 2026 Jefferies Global Healthcare Conference in New York City

Presentation time window 9:55 AM–10:25 AM EDT Jefferies Global Healthcare Conference session

Webcast replay duration Approximately six months Replay of conference presentation available on company website

Trial phase for GX-03 Phase 2 Randomized controlled trial in moderate-to-severe atopic dermatitis

Topline results timing Mid-2026 Expected timing for GX-03 Phase 2 topline data

Key Terms

Regulation FD Disclosure, Phase 2 randomized controlled trial, atopic dermatitis, cytokines, +2 more

6 terms

Regulation FD Disclosure regulatory

"Item 7.01 Regulation FD Disclosure. On May 19, 2026, Turn Therapeutics Inc. issued a press release"

Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.

Phase 2 randomized controlled trial financial

"It is currently being evaluated in a Phase 2 randomized controlled trial, with topline results expected"

atopic dermatitis medical

"currently in development for the treatment of moderate-to-severe atopic dermatitis"

A chronic inflammatory skin condition, often called eczema, that causes dry, itchy, red patches and recurring flare-ups; think of it as a persistent rash that can come and go over a person’s life. It matters to investors because its chronic nature and large patient population create steady demand for treatments, influence drug development and approval decisions, affect healthcare costs and reimbursement, and can drive revenue and valuation shifts for companies working on therapies and diagnostics.

cytokines medical

"specifically targeting IL-36 and IL-31, two cytokines that play distinct but interconnected roles"

Small proteins produced by immune and other cells that act as on/off signals or “text messages,” telling cells to ramp up, calm down, grow, or move during infection, injury, or disease. Investors watch cytokines because they are common drug targets and biomarkers—changes in cytokine activity can make a therapy work, cause serious side effects, or determine clinical trial and regulatory outcomes, all of which affect a company’s value.

topline results financial

"It is currently being evaluated in a Phase 2 randomized controlled trial, with topline results expected in mid-2026."

Topline results are the initial, high-level summary of the most important outcomes from an event such as a clinical trial or a company reporting period — for a drug study this means whether the main goals were met and basic safety info, and for a company it often means headline revenue and profit figures. Investors care because these summaries act like a headline that quickly signals whether prospects have improved or worsened, often driving immediate market reactions before the full details are released.

non-systemic topical inhibitor medical

"Its lead investigational therapy, GX-03, is a first-in-class, non-systemic topical inhibitor"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Turn Therapeutics (TTRX) disclose in this 8-K filing?

Turn Therapeutics disclosed that CEO Bradley Burnam will present at the Jefferies Global Healthcare Conference. The filing also describes lead therapy GX-03 and notes it is in a Phase 2 trial, with topline results expected in mid-2026 for moderate-to-severe atopic dermatitis.

When and where will Turn Therapeutics (TTRX) present at the Jefferies Global Healthcare Conference?

Turn Therapeutics will present at the Jefferies Global Healthcare Conference in New York City on June 4, 2026. The presentation is scheduled from 9:55 AM to 10:25 AM EDT and will feature CEO Bradley Burnam discussing the company’s clinical-stage programs.

How can investors access Turn Therapeutics’ (TTRX) Jefferies conference presentation?

Investors can access a live webcast of Turn Therapeutics’ presentation through the Investors section of its website. A replay of the webcast will be available on the Turn Therapeutics site for approximately six months following the June 4, 2026 presentation.

What is GX-03, Turn Therapeutics’ lead investigational therapy?

GX-03 is a first-in-class, non-systemic topical inhibitor for moderate-to-severe atopic dermatitis. It targets inflammatory cytokines IL-36 and IL-31 to address chronic skin inflammation and itch. The treatment is designed as a localized therapy for inflammatory dermatological conditions with high unmet medical need.

What clinical stage is Turn Therapeutics’ (TTRX) GX-03 program in?

GX-03 is currently being evaluated in a Phase 2 randomized controlled trial. The therapy targets IL-36 and IL-31 pathways in atopic dermatitis. Turn Therapeutics expects topline results from this Phase 2 study in mid-2026, providing key efficacy and safety insights for the program.

How does GX-03 target inflammatory pathways in atopic dermatitis?

GX-03 is designed to modulate IL-36 upstream and IL-31 downstream in the inflammatory cascade. IL-36 is associated with epithelial stress and barrier disruption, while IL-31 is linked to itch signaling. Addressing both helps tackle chronic skin inflammation and the itch-scratch cycle in eczema.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/19/2026 - 08:15 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 19, 2026

TURN THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware		001-42875		32-0456090
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

250 N. Westlake Blvd., Westlake Village, California		91362
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (818) 564-4011

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share		TTRX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On May 19, 2026, Turn Therapeutics Inc. issued a press release (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K and the Press Release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated May 19, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TURN THERAPEUTICS INC.
Date: May 19, 2026
	By:	/s/ Bradley Burnam
	Name:	Bradley Burnam
	Title:	Chief Executive Officer

Exhibit 99.1

FOR IMMEDIATE RELEASE

Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026

Westlake Village, Calif. – May 19, 2026 - Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference in New York City as follows:

Date: June 4, 2026

Time: 9:55AM – 10:25 AM EDT

A live webcast of the presentation may be accessed on the Investors section of the Turn Therapeutics website at https://ir.turntherapeutics.com/news-events/presentations. A replay of the webcast will be available on the Turn Therapeutics website for approximately six months following the presentation.

About Turn Therapeutics

Turn Therapeutics is a biotechnology company focused on developing innovative, precision therapies that target the underlying causes of inflammatory diseases with high unmet needs. Its lead investigational therapy, GX-03, is a first-in-class, non-systemic topical inhibitor currently in development for the treatment of moderate-to-severe atopic dermatitis. This therapy is designed to modulate key inflammatory pathways involved in eczema and other inflammatory dermatological conditions, specifically targeting IL-36 and IL-31, two cytokines that play distinct but interconnected roles in driving chronic skin inflammation and the itch-scratch cycle. GX-03 addresses IL-36 upstream, where epithelial stress and barrier disruption initiate the inflammatory cascade, and IL-31 downstream, where itch signaling perpetuates disease. It is currently being evaluated in a Phase 2 randomized controlled trial, with topline results expected in mid-2026.

Investor Relations / Media Contact

Sasha Damouni

Damouni Group LLC

Sasha@damounigroup.com

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

EX-99.1 PRESS RELEASE, DATED MAY 19, 2026 4.3 KB